

2023 EPPIA DISCLOSURE (inc. Vaccines Europe)
Date of publication: 28th of June 2024

	Full Name	HCPs: City of Principal Practice HCOs: city where registered	Country of Principal Practice	Principal Practice Address	Unique Country identifier (OPTIONAL)	Donations and Grants to HCOs and POs	Contribution to costs of Events			Fee for service and cost	
							Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation		Fees excl. VAT
INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up; information should be available for the individual Recipient or public authorities' consultation only, as appropriate)											
HCPs	Morten Brandengen	Oslo	Norway	diakonhjemmet, Oslo		N/A	N/A			10,000	
	Svein Dueland	Oslo	Norway	Kreftklinikken		N/A	N/A			7200	
	Inger Marie Laes	Bergen	Norway	Bergen hospital		N/A	N/A			7200	
	Eva Hofslil	Trondheim	Norway	Kreftklinikken		N/A	N/A			7200	
	Arne Westergaard	Oslo	Norway	Afdeling kreftbehandling		N/A	N/A			7200	
							N/A	N/A			
OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons											
Aggregate amount attributable to transfers of value to such Recipients						N/A	N/A				
Number of Recipients in aggregate disclosure						N/A	N/A				
% of the number of Recipients included in the aggregate disclosure in the total number, by category, of Recipients disclosed						N/A	N/A				
INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up; information should be available for the individual Recipient or public authorities' consultation only, as appropriate)											
HCOs	Norsk Gastrointestinal Cancer Gruppe	Grant to support the meeting the 27-28th of April 2023				35,000 NOK					
	Nordic AML Group 2023	Grant to support the meeting the 24-25th of August 2023				55,000 NOK					
	Onkologisk Forum Norge	Grant to support the meeting the 16-17th of November 2023				50,000 NOK					
OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons											
Aggregate amount attributable to transfers of value to such Recipients						N/A	N/A				
Number of Recipients in aggregate disclosure						N/A	N/A				
% of the number of Recipients included in the aggregate disclosure in the total number, by category, of Recipients disclosed						N/A	N/A				
INDIVIDUAL NAMED DISCLOSURE - one line per PO (i.e. all transfers of value during a year for an individual PO will be summed up; information should be available for the individual Recipient or public authorities' consultation only, as appropriate)											
POs											
	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons										
	Aggregate amount attributable to transfers of value to such Recipients						N/A	N/A			
Number of Recipients in aggregate disclosure						N/A	N/A				
% of the number of Recipients included in the aggregate disclosure in the total number, by category, of Recipients disclosed						N/A	N/A				
AGGREGATE DISCLOSURE											
Transfers of Value in Research & Development as defined											

